Resource Summary Report

Generated by dkNET on Sep 3, 2026

PEO1

RRID:CVCL_2686
Type: Cell Line

Proper Citation

RRID:CVCL_2686

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2686

Proper Citation: RRID:CVCL_2686

Description: Cell line PEO1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: BRCA2 syndrome

Defining Citation: PMID:1348364, PMID:3167863, PMID:3583449, PMID:8824553, PMID:9041185, PMID:19654294, PMID:20581869, PMID:22183581, PMID:22328975, PMID:22710073, PMID:23415752, PMID:25230021, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26589293, PMID:27235858, PMID:27397505, PMID:27561551, PMID:28196595, PMID:30894373, PMID:30971826, PMID:35028612, PMID:35839778

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PEO1

Synonyms: PE01, PEO-1, PEO

Cross References: BTO:BTO_0005796, EFO:EFO_0005445, ArrayExpress:E-MTAB-691, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:992, BioSample:SAMN03473296, cancercelllines:CVCL_2686, CancerTools:151672, Cell_Model_Passport:SIDM00472, ChEMBL-Cells:CHEMBL4295441, ChEMBL-Targets:CHEMBL4296485, Cosmic:991317,

Cosmic:1102826, Cosmic:1305316, Cosmic:1524353, Cosmic:1709263, Cosmic-CLP:1480372, DepMap:ACH-001630, ECACC:10032308, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1480372, GEO:GSM185145, GEO:GSM185146, GEO:GSM459703, GEO:GSM459853, GEO:GSM711726, GEO:GSM723253, GEO:GSM743505, GEO:GSM851938, GEO:GSM1340589, GEO:GSM1670347, GEO:GSM4973221, GEO:GSM4973227, GEO:GSM4973233, GEO:GSM4973239, GEO:GSM4973245, GEO:GSM4973251, GEO:GSM4973257, GEO:GSM4973263, GEO:GSM4973269, PharmacoDB:PE01_1260_2019, PRIDE:PXD003668, PRIDE:PXD020764, PRIDE:PXD030304, Progenetix:CVCL_2686, PubChem_Cell_line:CVCL_2686, Wikidata:Q54947162, Ximbio:151672

ID: CVCL_2686

Record Creation Time: 20220427T221430+0000

Record Last Update: 20260904T015434+0000

Ratings and Alerts

No rating or validation information has been found for PEO1.

No alerts have been found for PEO1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Yamamoto TM, et al. (2026) Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. Molecular cancer therapeutics, 25(7), 1130.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. Advanced biology, 10(3), e00404.

Szmyd R, et al. (2025) Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. Nature cell biology, 27(1), 59.

Woodruff ER, et al. (2025) Ablation of hematopoietic stem cell derived adipocytes reduces tumor burden in syngeneic mouse models of high-grade serous carcinoma. bioRxiv : the preprint server for biology.

Lake RJ, et al. (2025) Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. Cancer research communications, 5(10), 1796.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Molecular cancer therapeutics, 24(8), 1252.

Nie H, et al. (2024) Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. Nature communications, 15(1), 2853.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Leuzzi G, et al. (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell, 187(4), 861.

Persenaire C, et al. (2024) VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. Molecular carcinogenesis, 63(7), 1248.

Iwanaga R, et al. (2024) Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. Cancer research communications, 4(8), 1919.

Pasquesi GIM, et al. (2024) Regulation of human interferon signaling by transposon exonization. Cell, 187(26), 7621.

Nguyen LL, et al. (2024) Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Molecular cancer therapeutics, 23(9), 1332???1347.

McMellen A, et al. (2023) ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Molecular cancer research : MCR, 21(1), 3.

Pasquesi GIM, et al. (2023) Regulation of human interferon signaling by transposon exonization. bioRxiv : the preprint server for biology.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell reports, 42(10), 113307.

Lombardi S, et al. (2023) Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. Cancer research communications, 3(6), 1067.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.